However, the combination of pertuzumab with neoadjuvant trastuzumab and chemotherapy has been identified as a cost-saving option for specific subgroups of patients with HER2-positive breast cancer [11, 12]. The gene discussed is ERBB2; the disease is breast carcinoma.